This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ingevity Gains 24% in 6 Months: What's Driving the Stock?
by Zacks Equity Research
Encouraging outlook and upbeat prospects from the Georgia-Pacific's pine chemicals business buyout drive Ingevity's (NGVT) shares.
CBT vs. PPG: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CBT vs. PPG: Which Stock Is the Better Value Option?
Cleveland-Cliffs Wraps Up Full Redemption of Notes Due 2020
by Zacks Equity Research
Cleveland-Cliffs' (CLF) latest move lowers annualized interest expense by roughly $10 million.
PPG Projects Higher Costs, Soft Demand to Hit Q3 Earnings
by Zacks Equity Research
PPG projects adjusted earnings in the band of $1.41-$1.45 per share for the third quarter of 2018.
5 Reasons That Make Nucor (NUE) Stock a Solid Pick Now
by Anindya Barman
Upbeat outlook and strong growth prospects make Nucor (NUE) an attractive choice for investment.
Celanese Set to Raise Acetyl Intermediates Products Prices
by Zacks Equity Research
Celanese (CE) takes appropriate pricing actions amid a volatile pricing environment for raw materials.
International Paper at a 52-Week Low: What's Taking It Down?
by Zacks Equity Research
Elevated costs and adverse foreign currency translation will likely hurt International Paper's (IP) share-price performance in the near term.
Cabot (CBT) Acquires Carbon Black Manufacturer in China
by Zacks Equity Research
Cabot's (CBT) latest acquisition will help it meet the growing needs of specialty carbons customers worldwide.
5 Reasons to Add Cabot (CBT) Stock to Your Portfolio Now
by Anindya Barman
Based on its compelling prospects, we believe Cabot (CBT) has plenty of upside potential.
Reasons Why You Should Hold Domtar (UFS) Stock Right Now
by Zacks Equity Research
Domtar's (UFS) results will be driven by improvement in paper shipments, despite freight cost inflation and adverse foreign currency-translation impact.
Praxair (PX) Scales 52-Week High: What's Driving the Rally?
by Zacks Equity Research
Anticipated merger with Linde, solid backlog and new order wins will likely drive Praxair's (PX) share-price performance in the near term.
Should Value Investors Pick Cabot Corporation (CBT) Stock?
by Zacks Equity Research
Is Cabot Corporation (CBT) a great pick from the value investor's perspective right now? Read on to know more.
Cabot Corporation (CBT) Unveils High Purity Charcoal Powder
by Zacks Equity Research
Cabot Corporation's (CBT) new Norit SX Super S charcoal powder is produced by high purity sustainable feedstocks, activation methods and washing steps.
Cabot (CBT) Set to Raise Global Prices of Activated Carbon
by Zacks Equity Research
Cabot (CBT) decides to raise activated carbon prices in response to escalating raw material costs and currency fluctuations.
Cabot (CBT) Up 20% in a Year: What's Driving the Stock?
by Anindya Barman
Forecast-topping earnings performance and upbeat prospects for Reinforcement Materials and Performance Chemicals segments have contributed to the run up in Cabot's (CBT) shares.
Why Is Cabot (CBT) Up 0.5% Since Last Earnings Report?
by Zacks Equity Research
Cabot (CBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cabot (CBT) Up 11% in 3 Months: What's Driving the Stock?
by Anindya Barman
Strong Q3 earnings and upbeat outlook for Reinforcement Materials and Performance Chemicals segments have contributed to the gain in Cabot's (CBT) shares.
Cabot (CBT) Earnings and Revenues Trump Estimates in Q3
by Zacks Equity Research
Cabot (CBT) expects strong performance across all segments in Q4.
Cabot (CBT) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cabot (CBT) delivered earnings and revenue surprises of 2.91% and 2.75%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Cabot (CBT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Cabot (CBT) is likely to see year-over-year revenue growth in Q3.
Cabot (CBT) Shares Up 10% QTD: What's Driving the Stock?
by Zacks Equity Research
Strong Q2 earnings and upbeat outlook for Reinforcement Materials and Performance Chemicals segments have contributed to the gain in Cabot's (CBT) shares
Cabot and Nexeo Expand Deal for Distribution in Canada
by Zacks Equity Research
Cabot's (CBT) latest move is likely to deliver meaningful benefits to its customers in Canada.
Why Cabot (CBT) Stock Might be a Great Pick
by Zacks Equity Research
Cabot (CBT) could be an interesting play for investors as it is seeing solid earnings estimate revision in addition to having a robust industry rank.
Cabot (CBT) Up 12.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Cabot (CBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cabot (CBT) to Exhibit Activated Carbon Products at ACHEMA
by Zacks Equity Research
Cabot (CBT) is set to showcase Norit range from activated carbon families at ACHEMA 2018, Germany, that will assist in catalyst application.